Due to the consistent overexpression of PSMA in especially hormone-refractory and metastatic prostate cancer, this cell surface enzyme represents an excellent target for high-contrast PET imaging and also for therapeutic applications. Here, FOLH1 is linked to metastatic prostate carcinoma.